tbuckley/cabot-search huggingface dataset:
Survey of Postnatal Care
Authors: Frances M Cranfield
Journal: Journal of the Royal Society of Medicine (1983)

A postal survey of the postnatal care received by 250 mothers during the three months after delivery in the North Herts Maternity Unit achieved a response rate of 74.6%. More than 80% of mothers responding felt that they had received adequate help from the hospital staff, community midwife and health visitor but only 50% felt that they had received adequate help from their general practitioner. There seemed to be a need for some relaxation of the policy of length of hospital stay, an increase in the level of postnatal instruction and improvement in the interaction between general practitioner and mothers.
James Patrick Payne
Authors: Jacqueline Payne
Journal: BMJ (2016)

James Patrick Payne, known to his friends as Jimmy, was born in Dalkeith, near Edinburgh, the eldest of four children. His family then moved to Larkhall, Lanarkshire, when his father got a job there as a pharmacist. After his father died from the late effects of mustard gas when James was 14, his mother took her four children to live with their grandmother in Leith. Jimmy was not always destined to be a doctor. On being sacked from his first job in a canning factory, he decided he never wanted to be out of work again. He considered either becoming a union man or studying for a profession. To the eternal disappointment of his mother, who had hoped he would become a Catholic priest, he chose medicine. He became a student at the University of Edinburgh, financing his way by working on the railway. He was a fireman on the Mallard, when it ran on the east coast London to Edinburgh line and, on one memorable occasion, burnt the furniture in the first class coach to get it over Highgate Hill.

He was a student during the war when, while on army training corps exercises, he suffered a detached retina as a result of a thunder flash exploding. Unable to read for several weeks, he volunteered at the surgical outpatient department at the hospital in Leith, in the dock …
9p21.3 Coronary Artery Disease Risk Variants Disrupt TEAD Transcription Factor–Dependent Transforming Growth Factor β Regulation of p16 Expression in Human Aortic Smooth Muscle Cells
Authors: Naif A. M. Almontashiri, Darlène Antoine, Xun Zhou, Ragnar O. Vilmundarson, Sean X. Zhang, Kennedy N. Hao, Hsiao-Huei Chen, Alexandre F. R. Stewart
Journal: Circulation (2015)

The mechanism whereby the 9p21.3 locus confers risk for coronary artery disease remains incompletely understood. Risk alleles are associated with reduced expression of the cell cycle suppressor genes CDKN2A (p16 and p14) and CDKN2B (p15) and increased vascular smooth muscle cell proliferation. We asked whether risk alleles disrupt transcription factor binding to account for this effect.A bioinformatic screen was used to predict which of 59 single nucleotide polymorphisms at the 9p21.3 locus disrupt (or create) transcription factor binding sites. Electrophoretic mobility shift and luciferase reporter assays examined the binding and functionality of the predicted regulatory sequences. Primary human aortic smooth muscle cells (HAoSMCs) were genotyped for 9p21.3, and HAoSMCs homozygous for the risk allele showed reduced p15 and p16 levels and increased proliferation. rs10811656 and rs4977757 disrupted functional TEF-1 TEC1 AbaA domain (TEAD) transcription factor binding sites. TEAD3 and TEAD4 overexpression induced p16 in HAoSMCs homozygous for the nonrisk allele, but not for the risk allele. Transforming growth factor β, known to activate p16 and also to interact with TEAD factors, failed to induce p16 or to inhibit proliferation of HAoSMCs homozygous for the risk allele. Knockdown of TEAD3 blocked transforming growth factor β-induced p16 mRNA and protein expression, and dual knockdown of TEAD3 and TEAD4 markedly reduced p16 expression in heterozygous HAoSMCs.Here, we identify a novel mechanism whereby sequences at the 9p21.3 risk locus disrupt TEAD factor binding and TEAD3-dependent transforming growth factor β induction of p16 in HAoSMCs. This mechanism accounts, in part, for the 9p21.3 coronary artery disease risk.
Imatinib (STI 571)/ plus hydroxyurea: Safety and efficacy in pre-treated, progressive Glioblastoma Multiforme (GBM) patients (pts): An update on the initial 30 pts
Authors: G. Dresemann
Journal: Journal of Clinical Oncology (2005)

1516 Background: GBM is one of the most aggressive malignancies with a median survival of about 1 year. In newly diagnosed GBM combined treatment including surgery and chemo-/ radiotherapy leads to 2 years progression free survival (PFS) of 11% and 2 years overall survival of 26%. In recurrent GBM prognosis is even worse. Many malignancies of the brain including GBM express platelet derived growth factor receptors (PDGF-R). Imatinib, a tyrosine kinase inhibitor of Bcr-Abl, PDGF-Rs and the Kit receptor, showed remarkable clinical efficacy in chronic myeloid leukaemia and gastrointestinal stromal tumours. In GBM, however, single agent efficacy was limited due to the blood brain barrier (BBB). Therefore Hydroxyurea (HU) which freely penetrates and potentially modulates the BBB was combined with Imatinib to study if efficacy could be improved. Methods: : From June 2001 to September 2003 30 GBM pts refractory to radiation therapy and chemotherapy containing ACNU and temozolomide were treated with Imatinib, 400 mg/day and HU, 1000 mg/day as continuous daily, oral dosing, followed by clinical examination and magnetic resonance imaging every 6 weeks. Results: All 30 pts are evaluable for safety and efficacy. Initial ECOG-performance status was 1–2, the median age was 44 yrs (16–71). Results after a median treatment period of 19 weeks (4–145) were one complete response (CR) lasting 12 months, 4 partial responses (PR) lasting a median of 3 months (3–29), 11 stable diseases (SD) for a median of 6 months (3–33) and 13 progressive disease (PD). There were no grade 3 or 4 toxicities. 26 deaths occurred. 2 pts died of pulmonary embolism and 24 pts of disease progression, 1 pt after a 2 years period of SD. Six months PFS was 32%, 2 years PFS was 13%, 4 pts remain alive without progression for 34, 28, 25 and 23 months, respectively. Conclusions: Combination of Imatinib and HU was well tolerated and effective in this group of recurrent, refractory GBM pts, with a response rate of 20% (CR + PR) and a clinical benefit rate of 57% (including SD), 2 years PFS was 13%. Based on these results, additional studies have been initiated to further explore this regimen. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis
Patient (PT) understanding of venous thromboembolism (VTE) risks associated with lenalidomide (Len) and thalidomide (Thal), previous clots, and current prophylaxis.
Authors: D. M. Courtney, A. T. Samaras, J. Titus, J. M. Mckoy, B. J. Edwards, S. M. Trifilio, S. M. Belknap, M. J. Fisher, D. P. West, C. L. Bennett
Journal: Journal of Clinical Oncology (2010)

e16512 Background: PTs takingLen and Thal alone or in combination with high dose dexamethasone are at risk for deep venous thrombosis (DVT) and pulmonary embolism (PE). PT and provider awareness of VTE and optimal means of prevention is relatively unknown. This ongoing cross-sectional survey assessed the following objectives: 1) PT understanding of VTE risk associated with Len and Thal, 2) previous history of VTE among these PTs, and 3) current prophylaxis. Methods: A novel collaboration was developed between the specialty service demonstration outpatient pharmacy site (Walgreens Pharmacy) at Northwestern, and the Research on Adverse Drug Events and Reports (RADAR) team. A survey was developed and administered to PTs who filled a prescription for Len or Thal between July 2009 and December 2009. This pharmacy is the primary on-site location for outpatient prescriptions associated with the NCI-designated Robert H. Lurie Comprehensive Cancer Center at Northwestern. Results: A total of 23 PTs met eligibility requirements; 74% consented (14 = Len, 3 = Thal). Indications included: multiple myeloma (12), myelodysplastic syndrome (3), plasma cell lymphoma (1) and unspecified (1). Mean age= 64 (95% CI 59-70), 71% male. The proportion indicating awareness of increased clot risk while on Len or Thal was 82% (57%-96%). However, only 47% reported physician recommendation of prophylaxis and only 3 were on low molecular weight heparin or warfarin. The majority of PTs with prophylaxis were on aspirin alone (5/8). Three PTs reported history of clots (DVT = 1, PE = 1, PE and DVT = 1); all of these reported no current prophylaxis. Conclusions: In this patient subset, there is a significant discordance between PT-physician awareness of VTE risk and VTE prophylaxis. Althoughthemajority of PTs were aware of increased clot risk, less than half reported physician recommendation of prophylaxis. Further work to identify new thrombosis incidence and optimal means of prophylaxis is needed. If prophylaxis options prove to be effective, both patient education and provider awareness stand as areas of potential improvement. No significant financial relationships to disclose.
CORRESPONDENCE
Authors: D. Oscier, J. Bramble, E. Hodges, D. Wright
Journal: Journal of Clinical Oncology (2002)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.3.882 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11821481 CORRESPONDENCE Regression of Mucosa-Associated Lymphoid Tissue Lymphoma of the Bladder After Antibiotic Therapy D. OscierxD. OscierSearch for articles by this author , J. BramblexJ. BrambleSearch for articles by this author , E. HodgesxE. HodgesSearch for articles by this author , D. WrightxD. WrightSearch for articles by this author Show More Royal Bournemouth Hospital, Bournemouth, United KingdomSouthampton University Hospital, Southampton, United Kingdom https://doi.org/10.1200/JCO.2002.20.3.882 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Abstract 16041: Abnormal Pauses and Altered Sarcoplasmic Reticulum Calcium Cycling in Sinoatrial Myocytes Cause Bradycardia in a Recessive Model of CPVT
Authors: Anuradha Kalyanasundaram, Qing Lou, Alexey V Glukhov, Peter J Mohler, Björn C Knollmann, Muthu Periasamy, Sandor Gyorke, Vadim V Fedorov
Journal: Circulation (2013)

Aims: Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) patients exhibit bradycardia and atrial arrhythmias for which the underlying mechanism(s) remain unknown. We hypothesized that alt...
The Discrete Phases of the Cell Cycle: Autoradiographic, Physical, and Chemical Evidences
Authors: Claudio Nicolini
Journal: JNCI Journal of the National Cancer Institute (1975)

Recently the discrete model of the cell cycle, described as a series of metabolic progressions through four distinct phases, has been challenged by a few curves of percent labeled mitoses (PLM) and related autoradiographic data, which have been questionably interpreted in terms of a "continuous" cell cycle model. This conclusion is based in part on a few questionable observations which we summarize, along with our objections and explanations. We present a critical analysis of the autoradiographic data obtained with the PLM, in terms of the limitations and inconveniences of the technique itself. Some attention is paid to the usefulness of the "radioautographic transfer function," which seems an arbitrary mathematical expression of old autoradiographic observations. Finally, a review is presented of the old (by autoradiography) and new (by physical, chemical, and computer image analysis) evidences of the existence of dicrete phases in the cell cycle, which in turn support the idea of an all-or-none phenomenon for DNA synthesis, and which rule out the hypothesis of a continuous cell cycle model with a varying DNA synthesis rate function.
Effect of Intestinal Microflora on 3,2′-Dimethyl-4-aminobiphenyl-Induced Carcinogenesis in F344 Rats2
Authors: Bandaru S. Reddy, K. Watanabe
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Effect of Intestinal Microflora on 3,2′-Dimethyl-4-aminobiphenyl-Induced Carcinogenesis in F344 Rats Get access Bandaru S. Reddy, Bandaru S. Reddy 3Naylor Dana Institute for Disease Prevention, American Health Foundation, 1 Dana Rd., Valhalla, N.Y. 10595. Address reprint requests to Dr. Tobler Search for other works by this author on: Oxford Academic PubMed Google Scholar K. Watanabe K. Watanabe 3Naylor Dana Institute for Disease Prevention, American Health Foundation, 1 Dana Rd., Valhalla, N.Y. 10595. 4Present address: Kagoshima University School of Medicine, 1208-1, Usuki-cho, Kagoshima 890, Japan. 5We thank Dr. John H. Weisburger for the critical review of the manuscript and gratefully acknowledge the expert technical assistance of Mr. Yves M. Louis and Ms. Catherine Highland. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 61, Issue 5, November 1978, Pages 1269–1271, https://doi.org/10.1093/jnci/61.5.1269 Published: 01 November 1978 Article history Received: 08 February 1978 Accepted: 05 June 1978 Published: 01 November 1978
Fully human monoclonal antibodies to PSMA selectively target cytotoxins, radiotoxins and host immunity to prostate cancer
Authors: D. Ma, J. P. Gardner, C. E. Hopf, M. A. Cohen, G. P. Donovan, N. Schuelke, W. F. Goeckeler, W. C. Olson
Journal: Journal of Clinical Oncology (2004)

2546 Background: Prostate-specific membrane antigen (PSMA) is a type-2 membrane protein that is expressed abundantly on the surface of prostate cancer cells but not on normal human tissues. Furthermore, levels of PSMA expression increase with disease progression and are highest in hormone refractory and metastatic disease. This expression profile makes PSMA an attractive target for targeted antibody therapies for prostate cancer. We have evaluated fully human monoclonal antibodies (mAbs) against PSMA in preclinical settings in anticipation of human clinical trials. Methods: Using novel recombinant forms of PSMA and XenoMouse™ technology (Abgenix, Fremont, CA), we generated a panel of fully human IgG1 mAbs against PSMA. Characterization of these antibodies was conducted using a battery of Biacore, ELISA, flow cytometry, anti- PSMA Western blot and other functional assays. We have evaluated the mAbs' intrinsic cytotoxic effects as well as their ability to specifically deliver cytotoxic agents to PSMA-expressing tumor cells in vitro and in vivo. Results: We demonstrated that these mAbs specifically recognize conformational epitopes on PSMA with sub-nanomolar affinity. Naked mAbs reproducibly induced antibody-dependent cell-mediated cytotoxicity (ADCC) of human prostate cancer cells at nanomolar concentrations in vitro. Toxin-conjugated mAbs rapidly internalized and killed PSMA-expressing tumor cells with picomolar potency and >1000-fold selectivity, and long-term eradication of tumor was obtained without toxicity in mice xenografted with C4.2 cells. Similarly, mAbs labeled with a therapeutic beta-emitting isotope, 177Lu, selectively targeted PSMA-expressing xenografts, with a tumor uptake of 30% injected dose per gram of tumor. A single 400 μCi dose of 177Lu-labeled antibody was well tolerated and increased median survival times in the animals by 3.5 fold compared to untreated control animals (p<0.005). Conclusions: Based on these studies, a lead fully human antibody has been selected for human clinical testing in naked, radiolabeled and toxin-conjugated forms. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration PSMA Development Co. LLC
Phase 2 study of sunitinib in refractory thyroid cancer
Authors: E. E. Cohen, B. M. Needles, K. J. Cullen, S. J. Wong, J. L. Wade III, S. P. Ivy, V. M. Villaflor, T. Y. Seiwert, K. Nichols, E. E. Vokes
Journal: Journal of Clinical Oncology (2008)

6025 Background: Few treatment options exist for patients with refractory differentiated (including papillary, follicular, and Hurthle cell) and medullary thyroid cancers (DTC and MTC, respectively). Recent data suggest that thyroid cancers respond to antiangiogenic agents; in addition a subgroup of thyroid cancers harbor activating alterations in the RET gene. Sunitinib, has inhibitory activity against RET, VEGFR, and PDGFR, and thus has potential to be active in both DTC and MTC. Methods: Adult patients with DTC or MTC, refractory to curative treatment (surgery, external beam radiotherapy, or radioactive iodine (RAI) were required to have evidence of progressive disease within 6 months of study entry, ECOG performance status 0–2, and normal organ and bone marrow function. Treatment consisted of 6 week cycles of sunitinib malate 50 mg QD on a 4-week on/2-week off schedule. Primary endpoint was RECIST and biochemical response rate. Results: 43 subjects (37 DTC, 6 MTC) were enrolled; 25 male, 18 female; median age 58. 34/37 DTC subjects received prior RAI. 6 subjects received prior systemic therapy. 22 and 21 subjects had ECOG PS 0 and 1, respectively. The most common drug related adverse events and incidence included fatigue (79%), diarrhea (56%), palmar-plantar erythrodysesthesia (53%), neutropenia (49%), and hypertension (42%). Grade 3–4 toxicity included neutropenia (26%), thrombocytopenia (16%), hypertension (16%), fatigue (14%), palmar-plantar erythrodysesthesia (14%), and gastrointestinal tract events (14%, 2 diarrhea, 1 tracheo-esophageal fistula, 1 gastric hemorrhage, 1 gastric ulcer, and 1 gastritis). Best response in 31 evaluable DTC patients who completed 2 cycles was PR 13%, SD 68%, PD 10%, and NE 13%. Best response in MTC patients was SD 83%, PD 17%. Conclusions: In patients with refractory DTC or MTC who have evidence of progressive disease, sunitinib at the 50 mg 4/2 schedule is able to induce responses or disease stabilization in the great majority. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pfizer
School-Based Myopia Prevention Effort
Authors: M. Hossein Nowroozzadeh
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rhinitis predicts asthma
Authors: O Mikulich
Journal: Thorax (2009)

Asthma and allergic rhinitis are thought to be associated, but the exact relationship is not clear. This study investigated the onset of asthma in patients with allergic and non-allergic rhinitis, analysing follow-up data from the European Community Respiratory Health Survey (ECRHS).

Adults were randomly selected from responders to a questionnaire in ECRHS I. These individuals provided a …
Abstract 11368: Pre-Procedural Hemoglobin Level Predicts Mortality in Patients Undergoing Peripheral Vascular Interventions
Authors: Zehra Jaffery, Lior Shamai, Christopher J White
Journal: Circulation (2010)

Background: The pre-procedural serum hemoglobin (H) level is a well known predictor of all-cause mortality in patients undergoing percutaneous coronary interventions. However, the prognostic value ...
A phase Ib/2, dose-escalating, safety, and efficacy study of imprime PGG, cetuximab and irinotecan in patients with advanced colorectal cancer (CRC)
Authors: M. E. Tamayo, G. H. Cornelio, J. B. Bautista, M. L. Flores, M. R. Kurman, M. M. Paul, M. A. Gargano, M. L. Patchen
Journal: Journal of Clinical Oncology (2009)

e15062 Background: Imprime PGG (Imprime PGG Injection) is a ß-glucan polymer being developed for treatment of cancer in combination with complement-activating monoclonal antibodies. This trial evaluates the safety and efficacy of Imprime PGG in combination with cetuximab and irinotecan in CRC patients (pts). Methods: Pts with recurrent/progressive CRC (Karnofsky &gt; 70%) previously treated with 5-FU (alone or combined with other therapies) were treated with Imprime PGG (weekly), cetuximab (weekly; loading dose 400 mg/m2, then 250 mg/m2), and irinotecan (wks 1–4 of each 6-wk cycle; 125 mg/m2). In a 3 + 3 design, Imprime PGG dosing started at 2 mg/kg and escalated to 4 and 6 mg/kg after safety review. Safety (primary endpoint) was assessed by adverse events (AEs) and efficacy (secondary endpoint) by RECIST. Results: Imprime PGG was dosed in 3 pts at 2 mg/kg, 6 pts at 4 mg/kg and 1 pt at 6 mg/kg. Median age was 56. One pt remains on therapy at wk 49; other pts exited due to progressive disease (5 pts), irinotecan intolerance (2 pts), investigator discretion (1 pt), and withdrawn consent (1 pt). Median duration of treatment was 17.5 wks. No protocol-defined dose-limiting toxicities were observed. AEs experienced by &gt; 50% of pts included diarrhea (90%), hypokalemia, neutropenia (80%), weight loss (70%), anemia, anorexia, leucopenia (60%), alopecia, dry skin, hypomagnesemia, increased amylase, vomiting (50%). Grade 4 SAEs included increased amylase, increased lipase, and neutropenia. Partial response (PR) occurred in 3 pts (30%) and stable disease (SD) in 7 pts (70%), yielding a disease control rate (PR + SD) of 100%. The median time to progression was 22.3 wks. Conclusions: Imprime PGG combined with cetuximab and irinotecan in CRC pts was safe and efficacy warrants further investigation. [Table: see text]
Human Histology: A Textbook in Outline Form.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal